ARA:NYE-American Renal Associates Holdings, Inc (USD)

COMMON STOCK | Diagnostics & Research | NYE

Last Closing Price

USD 0.00

Change

0.00 (0.00)%

Market Cap

USD 0.40B

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

American Renal Associates Holdings, Inc. operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease. As of December 31, 2019, it operated 246 dialysis clinics in partnership with 400 nephrologist partners treating approximately 17,300 patients in 27 states and the District of Columbia. The company was founded in 1999 and is headquartered in Beverly, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-27 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
TMO Thermo Fisher Scientific Inc

+3.95 (+0.65%)

USD239.33B 28.18 19.52
DHR Danaher Corporation

-1.69 (-0.55%)

USD219.33B 38.94 26.42
DHR-PA Danaher Corporation

N/A

USD189.70B 261.66 N/A
IQV IQVIA Holdings Inc

-1.80 (-0.70%)

USD49.15B 65.47 24.01
A Agilent Technologies Inc

-2.93 (-1.85%)

USD47.89B 49.31 31.03
MTD Mettler-Toledo International I..

-8.69 (-0.59%)

USD34.00B 58.23 34.38
LH Laboratory Corporation of Amer..

-3.07 (-1.08%)

USD27.10B 14.45 6.59
PKI PerkinElmer Inc

-3.19 (-1.80%)

USD22.33B 16.83 13.16
WAT Waters Corporation

-0.89 (-0.25%)

USD22.22B 34.22 24.53
CRL Charles River Laboratories Int..

+0.24 (+0.06%)

USD21.66B 55.50 28.22

ETFs Containing ARA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Diagnostics & Research)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -11.36% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -11.36% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 32.10% N/A N/A N/A N/A
Risk Adjusted Return -35.39% N/A N/A N/A N/A
Market Capitalization 0.40B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Diagnostics & Research)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 154.10 N/A N/A N/A N/A
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio 10.25 N/A N/A N/A N/A
EV/EBITDA 9.37 N/A N/A N/A N/A
Management Effectiveness  
Return on Equity 17.51% N/A N/A N/A N/A
Return on Invested Capital 13.88% N/A N/A N/A N/A
Return on Assets 4.35% N/A N/A N/A N/A
Debt to Equity Ratio -681.00% N/A N/A N/A N/A
Technical Ratios  
Short Ratio 3.91 N/A N/A N/A N/A
Short Percent 4.43% N/A N/A N/A N/A
Beta 1.11 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:

There is nothing we particularly dislike